NCT07625800Recruiting
Switch to Ofatumumab and Level of Immunoglobulins
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up. The primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 115 (estimated)
- First submitted
- 15 May 2026
- Start date
- 12 Oct 2026
- Primary completion date
- Jun 2029
- Lead sponsor
- University Hospital, Lille
- Diseases
- Multiple sclerosis
- NCT number
- NCT07625800
What you commit to
- Study type: Observational
- Planned participants: 115
- From 12 Oct 2026 to the primary completion date, Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with ocrelizumab dose spacing \> 8 months in the last 18 months before switch
- Patient who underwent an immunoglobulin supplementation therapy within 18 months before the switch
Other
- Ongoing or planned pregnancy
Who the study is looking for
- Adult patients (≥ 18 years old) who had been treated with ocrelizumab for a relapsing form of Multiple Sclerosis according to the ocrelizumab marketing authorization (MA) treatment regimen for at least 18 months.
- Patients with a decrease of IgG at a minimum of two consecutive dosages (around six months apart) during ocrelizumab treatment\*.
- Patients already switched or switching from ocrelizumab to ofatumumab treatment (decision independent from the study\*).
- Patients agreeing to participate to the study.
- Able to provide their non-opposition
- At the discretion of the investigator, if a benefit for patients is expected based on their experience and depending on patient's characteristics
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.